TY - JOUR T1 - Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5 JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 735 LP - 740 DO - 10.1136/ijgc-00009577-200311000-00002 VL - 13 IS - 6 AU - M. A. Bookman AU - B. E. Greer AU - R. F. Ozols Y1 - 2003/10/01 UR - http://ijgc.bmj.com/content/13/6/735.abstract N2 - Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5. ER -